Climb Bio (CLYM) news
Recent news
Climb Bio Inc: Baird assumes coverage with outperform rating; target price $21
Baird analyst Nevin Varghese initiated coverage of Climb Bio (NASDAQ: CLYM) with an Outperform rating and a $21 price target, citing the company’s strong second-half 2026 catalyst profile and progress in its clinical development programs [13]. Climb Bio, a clinical-stage biotechnology company, is…
AInvest Wire · Aug 17, 2026Climb Bio - financing extends cash runway into second half of 2028
Climb Bio, Inc. (Nasdaq: CLYM) has extended its cash runway to the second half of 2028, according to updated financial guidance provided by the company. As of March 31, 2026, Climb Bio held $146.3 million in cash , cash equivalents, and marketable securities, with no debt on its balance sheet. This…
AInvest Wire · Aug 6, 2026Climb Bio Inc: RBC initiates coverage with outperform rating; target price $23
AInvest Wire · Aug 3, 2026Climb Bio added to Wedbush best ideas list; PT to $20 from $17
AInvest Wire · Jul 27, 2026Climb announces North American distribution partnership with Ivanti
AInvest Wire · Jun 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.